Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Volumn 17, Issue 3, 2003, Pages 207-210

  Simpson, Dene ^a   Noble, Stuart ^a   Perry, Caroline ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ECONOMICS; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS;

EID: 1542754678     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317030-00007     Document Type: Review

References (35)